Key result
Maternal pregestational diabetes links to ~3- to 5-fold higher congenital cardiopathy risk, driven by hyperglycemia.
Why the study?
Maternal pregestational diabetes increases the risk of congenital cardiopathies three- to five-fold, but the underlying molecular mechanisms remain incompletely understood.
Effect estimate: 3- to 5-fold increased risk
This review highlights the molecular mechanisms by which maternal pregestational diabetes increases the risk of congenital heart defects, emphasizing the teratogenic role of hyperglycemia.
Supports preconception counseling in diabetes; leaves open mechanistic targets for preventive trials.
Congenital heart defects (CHDs) are the most common form of birth defects in humans. They occur in 9 out of 1000 live births and are defined as structural abnormalities of the heart. Understanding CHDs is difficult due to the heterogeneity of the disease and its multifactorial etiology. Advances in genomic sequencing have made it possible to identify the genetic factors involved in CHDs. However, genetic origins have only been found in a minority of CHD cases, suggesting the contribution of non-inherited (environmental) risk factors to the etiology of CHDs. Maternal pregestational diabetes is associated with a three- to five-fold increased risk of congenital cardiopathies, but the underlying molecular mechanisms are incompletely understood. According to current hypotheses, hyperglycemia is the main teratogenic agent in diabetic pregnancies. It is thought to induce cell damage, directly through genetic and epigenetic dysregulations and/or indirectly through production of reactive oxygen species (ROS). The purpose of this review is to summarize key findings on the molecular mechanisms altered in cardiac development during exposure to hyperglycemic conditions in utero. It also presents the various in vivo and in vitro techniques used to experimentally model pregestational diabetes. Finally, new approaches are suggested to broaden our understanding of the subject and develop new prevention strategies.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2023) conducted a review in Congenital heart defects. Maternal pregestational diabetes was evaluated on Congenital cardiopathies (3- to 5-fold increased risk). Maternal pregestational diabetes is associated with a three- to five-fold increased risk of congenital cardiopathies, with hyperglycemia hypothesized as the main teratogenic agent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: